ClinicalTrials.gg
Sign In

Genital Neoplasms, Female clinical trials

The registry lists 81 studies for Genital Neoplasms, Female across more than 10 countries. 18 are recruiting or about to start. 36 of them are mainly about Genital Neoplasms, Female (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 13 narrower conditions too, such as Ovarian Neoplasms: 6,930 studies, 1,800 open.

Get an email when these change. Save the Genital Neoplasms, Female studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
36
Recruiting
14
Status unknown
10
Active, not recruiting
8
Terminated
6
Not yet recruiting
4

Phase

Phase 2
21
Phase 1
13
Phase 3
9
Early Phase 1
1

Where

United States
37
China
11
Spain
8
Italy
7
Belgium
7
United Kingdom
6

Who runs them

Eli Lilly and Company (4) · Xiaoxiang Chen (2) · M.D. Anderson Cancer Center (2) · KU Leuven (2) · Stanford University (1) · Manipal University (1) · National Cancer Institute (NCI) (1) · Novartis Pharmaceuticals (1)

What is being tested here

Drugs under test in Genital Neoplasms, Female studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Pembrolizumab103
Bevacizumab102
Dimenhydrinate101
Anti-TCR Vb6/Vb10/IL-2 Antibody Fusion Protein STAR0602101
Bulumtatug fuvedotin111
Lenvatinib101
Anlotinib002
Paclitaxel002
Carboplatin002
Niraparib002

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open · Immune checkpoint inhibitors 1 open · PARP inhibitors 3 · Antimetabolites 3

Coming up

1phase 3 study under way
7studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7

Who these studies take

Of the 14 Genital Neoplasms, Female studies recruiting now, 8 (57%) set no upper age limit and 5 (36%) stop at 75 or younger. 1 (7%) take children under 18. 12 (86%) are for women only and 0 (0%) for men only; 2 (14%) take healthy volunteers.

Recruiting studies that take each age, of 14
AgeWomenMen
101 (7%)0 (0%)
1811 (79%)2 (14%)
3013 (93%)2 (14%)
4014 (100%)2 (14%)
5014 (100%)2 (14%)
6513 (93%)2 (14%)
7512 (86%)2 (14%)
858 (57%)2 (14%)

Across all 81 studies, recruiting or not: 17% stop at 75 or younger and 9% at 65; 9% take children; 81% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Genital Neoplasms, Female studies take

Of 21 interventional studies with no phase under Genital Neoplasms, Female, half reached primary completion within 59 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase59 mo20–76 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Stopped1

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 81. Browse all 81 → or search them.